RT Journal Article
T1 Determination of the Elution Capacity of Dalbavancin in Bone Cements: New Alternative for the Treatment of Biofilm-Related Peri-Prosthetic Joint Infections Based on an In Vitro Study
A1 Sánchez Somolinos, M.
A1 Diez Navarro, Marta
A1 Benjumea, Antonio
A1 Tormo, Marta
A1 Matas, José
A1 Vaquero, Javier
A1 Muñoz, Patricia
A1 Muñoz García, Patricia Carmen
A1 Sanz Ruiz, Pablo
A1 Guembe, Maria
AB Antibiotic-loaded bone cement is the most widely used approach for the treatment of biofilm-induced septic sequelae in orthopedic surgery. Dalbavancin is a lipoglycopeptide that acts against Gram-positive bacteria and has a long half-life, so we aimed to assess whether it could be a new alternative drug in antibiotic-loaded bone cement for the treatment of periprosthetic joint infections. We assessed the elution capacity of dalbavancin and compared it with that of vancomycin in bone cement. Palacos®R (Heraeus Medical GmbH, Wehrheim, Germany) bone cement was manually mixed with each of the antibiotics studied at 2.5% and 5%. Three cylinders were obtained from each of the mixtures; these were weighed and incubated in 5 mL phosphate-buffered saline at 37°C under shaking for 1 h, 2 h, 4 h, 8 h, 24 h, 48 h, 168 h, and 336 h. PBS was replenished at each time point. The samples were analyzed using high-performance liquid chromatography (vancomycin) and mass cytometry (dalbavancin). Elution was higher than the minimum inhibitory concentration (MIC)90 for both antibiotics after 14 days of study. The release of vancomycin at 14 days was higher than of dalbavancin at each concentration tested (p = 0.05, both). However, the cumulative release of 5% dalbavancin was similar to that of 2.5% vancomycin (p = 0.513). The elution capacity of dalbavancin reached a cumulative concentration similar to that of vancomycin. Moreover, considering that the MIC90 of dalbavancin is one third that of vancomycin (0.06 mg/L and 2 mg/L, respectively) and given the long half-life of dalbavancin, it may be a new alternative for the treatment of biofilm-related periprosthetic infections when loaded in bone cement.
PB MDPI
YR 2022
FD 2022-09-13
LK https://hdl.handle.net/20.500.14352/117533
UL https://hdl.handle.net/20.500.14352/117533
LA eng
NO Sánchez-Somolinos, M., Díaz-Navarro, M., Benjumea, A., Tormo, M., Matas, J., Vaquero, J., Muñoz, P., Sanz-Ruíz, P., & Guembe, M. (2022). Determination of the elution capacity of dalbavancin in bone cements: New alternative for the treatment of biofilm-related peri-prosthetic joint infections based on an in vitro study. Antibiotics, 11(10), 1300. https://doi.org/10.3390/antibiotics11101300
DS Docta Complutense
RD 3 abr 2025